サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541355

卵巣がん市場レポート：タイプ別、治療タイプ別、エンドユーザー別、地域別、2024～2032年

Ovarian Cancer Market Report by Type, Treatment Type, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 140 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
卵巣がん市場レポート：タイプ別、治療タイプ別、エンドユーザー別、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の卵巣がん市場規模は2023年に21億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに51億米ドルに達し、2024～2032年の間に10.09％の成長率（CAGR）を示すと予測しています。卵巣がん罹患率の上昇、がん治療における個別化医療の台頭、認知度の向上、早期発見の促進、研究支援を目的とした政府のイニシアチブの実施が、市場を牽引する主要要因のひとつです。

卵巣がんは、卵子と女性ホルモンの産生を担う女性の生殖器官である卵巣から始まるがんの一種です。通常、卵巣内の異常細胞が制御不能に増殖し、腫瘍を形成することで発症します。卵巣がんにはさまざまなタイプがあり、その発生源となる特定の細胞に基づいて分類することができます。最も一般的なのは上皮性卵巣がんで、卵巣の表面から発生します。その他のあまり一般的でないタイプには、胚細胞腫瘍と間質腫瘍があり、それぞれ卵子とホルモンを産生する細胞から発生します。卵巣がんの一般的な症状には、腹部膨満感、骨盤または腹部の痛み、摂食困難やすぐに満腹になる感じ、頻尿、腸習慣の変化などがあります。

この市場を牽引しているのは、卵巣がん患者の世界の増加です。卵巣がんの罹患率の上昇により、医療プロバイダーや製薬会社は革新的な治療法や標的治療法を発見するための研究開発に多額の投資を行うようになっています。さらに、医療技術や診断技術の進歩により、卵巣がんの早期発見・診断が可能になり、医療従事者がより早い段階で治療を開始できるようになり、患者の転帰が改善され、生存率が向上しています。また、定期的な検診と早期発見の重要性に対する一般住民や医療専門家の意識の高まりは、卵巣がんに関連する死亡率の低下に重要な役割を果たしています。さらに、製薬会社と研究機関との戦略的提携や協力関係が、新規治療や個別化治療法の開発に道を開いています。さらに、医療インフラへの投資が増加し、いくつかの地域で有利な償還政策が利用できるようになったことで、患者が卵巣がんのタイムリーで包括的な治療を求めるようになっています。

卵巣がん市場傾向/促進要因

卵巣がんの有病率の増加

卵巣がんの有病率の上昇は、世界の卵巣がん市場の力学を形成する主要なドライバーです。卵巣がんは、世界中の女性が罹患する最も一般的な婦人科悪性腫瘍のひとつです。世界保健機関（WHO）によると、毎年何千もの症例が新たに診断されており、重大な健康上の懸念となっています。人口の高齢化と、座りがちな生活習慣や不健康な食生活を含む生活様式の変化が、卵巣がんの罹患率上昇の一因となっています。人口の高齢化に伴い、卵巣がんを発症するリスクは増加し、効果的な治療オプションに対する需要はさらに高まっています。このような卵巣がん患者の急増は、製薬会社や研究機関による広範な研究開発努力に拍車をかけ、市場の成長に影響を与えています。

医療技術と個別化医療における技術の進歩

医療技術と個別化医療の進歩は、卵巣がんの管理に新たな時代をもたらし、市場の重要な促進要因となっています。診断ツールや画像診断法は著しく進化し、卵巣がんの早期発見と正確な診断を可能にしています。経膣超音波試験、磁気共鳴画像法（MRI）、CA-125などの血清バイオマーカー試験は、卵巣がんを早期段階で発見する可能性を向上させ、治療成功の見込みを高めています。さらに、個別化医療の台頭は、卵巣がんを含むがん治療へのアプローチを一変させました。標的治療や免疫療法の開発はがん治療に革命をもたらし、個々の患者の腫瘍の特異的な分子的・遺伝的特徴に対処するオーダーメイド治療を提供しています。これらの精密治療は臨床試験で有望な結果を示しており、これまで治療選択肢が限られていた卵巣がん患者に新たな希望をもたらしています。

有利な償還政策の実施

医療インフラの拡大と有利な償還政策の存在は、世界の卵巣がん市場の成長を促進する上で極めて重要な役割を果たしています。各国の政府や医療当局は、がん治療センターや腫瘍科病棟を含む医療施設の強化にますます投資しています。この発展により、卵巣がんの医療サービス、診断、治療への患者のアクセスは大幅に改善されました。さらに、有利な償還政策が、がん治療を求める患者の経済的負担を軽減しています。診断試験、手術、化学療法、標的治療に対する償還支援により、治療費はより手頃になり、より幅広い層が治療を受けられるようになりました。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の卵巣がん市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 上皮性卵巣がん
  • 胚細胞卵巣がん
  • 間質細胞卵巣がん

第7章 市場内訳：治療タイプ別

  • 免疫療法
  • 化学療法
  • 標的療法
  • 手術
  • その他

第8章 市場内訳：エンドユーザー別

  • 病院
  • 在宅医療
  • 専門センター
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Amneal Pharmaceuticals Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Ovarian Cancer Market: Major Drivers and Challenges
  • Figure 2: Global: Ovarian Cancer Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Ovarian Cancer Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Ovarian Cancer Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Ovarian Cancer Market: Breakup by Treatment Type (in %), 2023
  • Figure 6: Global: Ovarian Cancer Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Ovarian Cancer Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Ovarian Cancer (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Ovarian Cancer (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Ovarian Cancer (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Ovarian Cancer (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Ovarian Cancer (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Ovarian Cancer (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Ovarian Cancer (Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Ovarian Cancer (Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Ovarian Cancer (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Ovarian Cancer (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Ovarian Cancer (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Ovarian Cancer (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Ovarian Cancer (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Ovarian Cancer (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Ovarian Cancer (Speciality Centre) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Ovarian Cancer (Speciality Centre) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Ovarian Cancer (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Ovarian Cancer (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Ovarian Cancer Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Ovarian Cancer Industry: SWOT Analysis
  • Figure 82: Global: Ovarian Cancer Industry: Value Chain Analysis
  • Figure 83: Global: Ovarian Cancer Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ovarian Cancer Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Ovarian Cancer Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Ovarian Cancer Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 4: Global: Ovarian Cancer Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Ovarian Cancer Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Ovarian Cancer Market: Competitive Structure
  • Table 7: Global: Ovarian Cancer Market: Key Players
目次
Product Code: SR112024A6407

The global ovarian cancer market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.09% during 2024-2032. The rising incidence of ovarian cancer cases, the emergence of personalized medicine in cancer care, and the implementation of government Initiatives to raise awareness, promote early detection, and support research represent some of the key factors driving the market.

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and female hormones. It typically develops when abnormal cells in the ovaries grow and multiply uncontrollably, forming a tumor. There are different types of ovarian cancer, and they can be classified based on the specific cells from which they originate. The most common type is epithelial ovarian cancer, which arises from the surface of the ovary. Other less common types include germ cell tumors and stromal tumors, which develop from the cells that produce eggs and hormones, respectively. Common symptoms of ovarian cancer include abdominal bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, frequent urination, and changes in bowel habits.

The market is driven by the increasing prevalence of ovarian cancer cases globally. The rising incidence of ovarian cancer has prompted healthcare providers and pharmaceutical companies to invest heavily in research and development to discover innovative therapies and targeted treatments. Moreover, advancements in medical technology and diagnostic techniques have led to early detection and diagnosis of ovarian cancer, enabling healthcare professionals to initiate treatment at earlier stages, improving patient outcomes, and enhancing survival rates. Besides, the growing awareness among the general population and healthcare professionals about the importance of regular screenings and early detection plays a crucial role in reducing mortality rates associated with ovarian cancer. Additionally, strategic collaborations and partnerships between pharmaceutical companies and research institutions have paved the way for the development of novel therapeutics and personalized treatment options. Furthermore, the rising investment in healthcare infrastructure and the availability of favorable reimbursement policies in several regions have encouraged patients to seek timely and comprehensive treatment for ovarian cancer.

Ovarian Cancer Market Trends/Drivers:

Growing prevalence of ovarian cancer

The escalating prevalence of ovarian cancer is a primary driver shaping the dynamics of the global ovarian cancer market. Ovarian cancer is one of the most common gynecologic malignancies affecting women worldwide. According to the World Health Organization (WHO), thousands of new cases are diagnosed each year, making it a significant health concern. The aging population and changing lifestyle patterns, including sedentary habits and unhealthy diets, have contributed to the rising incidence of ovarian cancer. As the population ages, the risk of developing ovarian cancer increases, further intensifying the demand for effective treatment options. This surge in ovarian cancer cases has spurred extensive research and development efforts by pharmaceutical companies and research institutions, which is influencing the market growth.

Technological advancements in medical technology and personalized medicine

Advancements in medical technology and personalized medicine have ushered in a new era in the management of ovarian cancer, constituting a significant driver in the market. Diagnostic tools and imaging modalities have evolved significantly, enabling early detection and accurate diagnosis of ovarian cancer. Transvaginal ultrasounds, magnetic resonance imaging (MRI), and serum biomarker tests, such as CA-125, have improved the chances of detecting ovarian cancer at its early stages, enhancing the prospects for successful treatment. Moreover, the rise of personalized medicine has transformed the approach to cancer treatment, including ovarian cancer. The development of targeted therapies and immunotherapies has revolutionized cancer care, offering tailored treatments that address the specific molecular and genetic characteristics of individual patients' tumors. These precision treatments have shown promising results in clinical trials, providing new hope for ovarian cancer patients who may have previously had limited treatment options.

Implementation of favorable reimbursement policies

The expansion of healthcare infrastructure and the presence of favorable reimbursement policies have played a pivotal role in driving the growth of the global ovarian cancer market. Governments and healthcare authorities in various countries are increasingly investing in bolstering healthcare facilities, including cancer treatment centers and oncology units. This development has significantly improved patient access to healthcare services, diagnosis, and treatment for ovarian cancer. Furthermore, favorable reimbursement policies have alleviated the financial burden on patients seeking cancer treatments. Reimbursement support for diagnostic tests, surgeries, chemotherapy, and targeted therapies has made treatment more affordable and accessible to a broader segment of the population.

Ovarian Cancer Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global ovarian cancer market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, treatment type and end user.

Breakup by Type:

Epithelial Ovarian Cancer

Germ Cell Ovarian Cancer

Stromal Cell Ovarian Cancer

Epithelial ovarian cancer represents the leading type

The report has provided a detailed breakup and analysis of the market based on the type. This includes epithelial ovarian cancer, germ cell ovarian cancer, and stromal cell ovarian cancer. According to the report, epithelial ovarian cancer represented the largest segment.

Epithelial ovarian cancer is more commonly diagnosed in older women, and as the global population ages, the incidence of ovarian cancer tends to increase. The risk of developing ovarian cancer rises significantly after menopause, making postmenopausal women more susceptible to this type of cancer. Moreover, obesity and unhealthy lifestyle choices, such as poor diet and lack of physical activity, have been associated with an increased risk of ovarian cancer. The global rise in obesity rates over the past few decades may have contributed to the growing prevalence of epithelial ovarian cancer. Besides, certain genetic mutations, such as BRCA1 and BRCA2 mutations, are known to increase the risk of developing ovarian cancer. Inherited genetic factors can play a significant role in the prevalence of epithelial ovarian cancer, especially in families with a history of the disease.

Breakup by Treatment Type:

Immunotherapy

Chemotherapy

Targeted Therapy

Surgery

Others

Immunotherapy is the most popular treatment type

A detailed breakup and analysis of the market based on the treatment type has also been provided in the report. This includes lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. According to the report, lateral flow assays hold the largest market share.

Immunotherapy has emerged as a revolutionary approach in cancer treatment, showing promising results in various cancer types. Ovarian cancer, being one of the deadliest gynecological malignancies, has been a focus of research to identify novel and more effective therapies. Immunotherapy's success in other cancer types has generated significant interest in exploring its potential benefits in ovarian cancer treatment. Moreover, immunotherapy focuses on targeting the tumor microenvironment, which includes various immune cells and signaling molecules that support tumor growth and progression. By modulating the immune response, immunotherapy aims to create an inhospitable environment for cancer cells, hindering their growth and spread.

Breakup by End User:

Hospitals

Homecare

Speciality Centre

Others

The report has provided a detailed breakup and analysis of the market based on end user. This includes hospitals, homecare, speciality centre, and others.

Hospitals are the primary healthcare institutions that play a crucial role in the diagnosis, treatment, and management of ovarian cancer. They offer a comprehensive range of medical services, including surgery, chemotherapy, radiation therapy, and supportive care for ovarian cancer patients. Hospitals typically have specialized oncology departments or cancer centers equipped with advanced medical technology and a multidisciplinary team of healthcare professionals, including oncologists, surgeons, nurses, and support staff.

Homecare services may include nursing care, administration of medications, pain management, wound care, and assistance with activities of daily living. Homecare is particularly beneficial for patients who require ongoing support and monitoring but prefer to receive treatment in a familiar environment. Homecare services aim to enhance the quality of life for ovarian cancer patients, allowing them to remain in their homes while receiving necessary medical attention.

Specialty centers are dedicated healthcare facilities that focus on specific medical conditions or diseases, including ovarian cancer. These centers offer specialized expertise, state-of-the-art facilities, and advanced treatment options tailored to the needs of ovarian cancer patients. Specialty centers include oncology clinics, cancer institutes, and women's health centers that provide comprehensive care, support, and access to cutting-edge therapies and clinical trials for ovarian cancer.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a well-established and technologically advanced healthcare infrastructure, with a high concentration of hospitals, specialty centers, and cancer institutes equipped with state-of-the-art medical facilities and cutting-edge technologies. This enables efficient diagnosis, treatment, and follow-up care for ovarian cancer patients. Moreover, the region is a hub for biomedical research and development, with numerous pharmaceutical and biotechnology companies conducting extensive research on cancer therapies, including ovarian cancer. Ongoing research and clinical trials contribute to the development of innovative treatment options and novel drugs, making North America a frontrunner in ovarian cancer treatment advancements.

Competitive Landscape:

The competitive landscape of the ovarian cancer market is characterized by a mix of pharmaceutical companies, biotechnology firms, and academic institutions actively engaged in research, development, and commercialization of treatments and therapies. These companies are developing and commercializing chemotherapy drugs, targeted therapies, and immunotherapies for ovarian cancer treatment. They are also focusing on novel drug development and personalized treatment options. Moreover, various companies are identifying new drug targets, exploring combination therapies, and conducting clinical trials to assess the safety and efficacy of their investigational drugs. They are also forming strategic partnerships with academic institutions, research organizations, and other biopharmaceutical firms to access complementary expertise, resources, and technologies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amneal Pharmaceuticals Inc.

AstraZeneca plc

Eli Lilly and Company

F. Hoffmann-La

Roche AG

GSK plc

Hikma Pharmaceuticals PLC

Lupin Limited

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Recent Developments:

In September 2022, AstraZeneca and Merck jointly declared that Lynparza (olaparib) had received approval in China for the maintenance treatment of adult patients diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval applies specifically to patients who have shown a complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.

In September 2022, Pfizer and Strata Oncology announced an expansion of their partnership to include a clinical trial that will evaluate multiple cancer therapies in novel, biomarker-guided patient cohorts.

Tesaro, which is now part of GlaxoSmithKline (GSK), launched "Zejula" (niraparib), another PARP inhibitor, for the treatment of ovarian cancer. Zejula is indicated for maintenance treatment in women with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

Key Questions Answered in This Report:

  • How has the global ovarian cancer market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global ovarian cancer market?
  • What is the impact of each driver, restraint, and opportunity on the global ovarian cancer market?
  • What are the key regional markets?
  • Which countries represent the most attractive ovarian cancer market?
  • What is the breakup of the market based on types?
  • Which is the most attractive types in the ovarian cancer market?
  • What is the breakup of the market based on treatment type?
  • Which is the most attractive treatment type in the ovarian cancer market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the ovarian cancer market?
  • What is the competitive structure of the global ovarian cancer market?
  • Who are the key players/companies in the global ovarian cancer market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ovarian Cancer Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Epithelial Ovarian Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Germ Cell Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Stromal Cell Ovarian Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Immunotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chemotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Targeted Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Surgery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Speciality Centre
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amneal Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AstraZeneca plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Hikma Pharmaceuticals PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Lupin Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis